| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acute promyelocytic leukemia
|
Tallman, Martin S.
|
|
2014
|
27 |
1 |
p. 1-
1 p.
|
article
|
| 2 |
Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
|
Grimwade, David
|
|
2014
|
27 |
1 |
p. 53-61
9 p.
|
article
|
| 3 |
Conventional induction and post-remission therapy in APL: Have we arrived?
|
Sanz, Miguel A.
|
|
2014
|
27 |
1 |
p. 33-38
6 p.
|
article
|
| 4 |
‘Corrigendum to “Chronic myelomonocytic leukemia: Myelodysplastic or myeloproliferative?” [Best Pract Res Clin Haematol (2013) 387–400]’
|
Itzykson, Raphael
|
|
2014
|
27 |
1 |
p. 79-
1 p.
|
article
|
| 5 |
Editorial Board / Aims & Scope
|
|
|
2014
|
27 |
1 |
p. iii-
1 p.
|
article
|
| 6 |
Extramedullary disease in APL: A real phenomenon to contend with or not?
|
Ganzel, Chezi
|
|
2014
|
27 |
1 |
p. 63-68
6 p.
|
article
|
| 7 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care
|
Iland, Harry J.
|
|
2014
|
27 |
1 |
p. 39-52
14 p.
|
article
|
| 8 |
Index
|
|
|
2014
|
27 |
1 |
p. I-
1 p.
|
article
|
| 9 |
The coagulopathy in acute promyelocytic leukaemia – What have we learned in the past twenty years
|
Kwaan, Hau C.
|
|
2014
|
27 |
1 |
p. 11-18
8 p.
|
article
|
| 10 |
Treatment of paediatric APL: How does the therapeutic approach differ from adults?
|
Kutny, Matthew A.
|
|
2014
|
27 |
1 |
p. 69-78
10 p.
|
article
|
| 11 |
Triple A therapy: The molecular underpinnings of the unique sensitivity of leukemic promyelocytes to anthracyclines, all-trans-retinoic acid and arsenic trioxide
|
Nichol, Jessica N.
|
|
2014
|
27 |
1 |
p. 19-31
13 p.
|
article
|
| 12 |
Understanding the molecular pathogenesis of acute promyelocytic leukemia
|
Lo-Coco, Francesco
|
|
2014
|
27 |
1 |
p. 3-9
7 p.
|
article
|
Journal description